m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis
Open Access
- 5 January 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 114
Abstract
Background: The pivotal roles of long noncoding RNAs (lncRNAs) in the realm of cancer biology, inclusive of bladder cancer (BCa), have been substantiated through various studies. Remarkably, RNA methylation, especially m6A modification, has demonstrated its influence on both coding and noncoding RNAs. Nonetheless, the explicit impact of RNA methylation on lncRNAs and its subsequent contribution to the progression of BCa remains to be elucidated. Methods: In the present investigation, we scrutinized the expression and m6A methylation status of LINC01106, employing quantitative real-time PCR (qRT–PCR) and methylated RNA immunoprecipitation (MeRIP)-qPCR. To decipher the regulatory mechanism underpinning LINC01106, we utilized RNA immunoprecipitation (RIP)-qPCR, methylated RNA immunoprecipitation (MeRIP) assays, and bioinformatic analysis. Furthermore, the CRISPR/dCas13b-METTL3-METTL14 system was implemented to probe the function of LINC01106. Results: The findings of our study indicated that LINC01106 is under expressed and exhibits diminished m6A methylation levels in BCa tissues when compared those of normal controls. A diminished expression of LINC01106 was associated with a less favorable prognosis in BCa patients. Intriguingly, CRISPR-mediated hypermethylation of LINC01106, facilitated by dCas13b-M3-M14, abolished the malignant phenotype of the BCa cells, an effect that could be inverted by Disabled-1 (DAB1) knockdown. From a mechanistic standpoint, we identified an m6A modification site on LINC01106 and highlighted YTHDC1 as a potential reader protein implicated in this process. Additionally, a positive correlation between DAB1 and LINC01106 expression was observed, with miR-3148 potentially acting as a mediator in this relationship. Conclusions: In summary, our research unveils a suppressive regulatory role of the LINC01106/miR-3148/DAB1 axis in the progression of BCa and underscores the YTHDC1-mediated m6A modification mechanism in regards to LINC01106. These revelations propose a new therapeutic target for the management of BCa.Keywords
Funding Information
- Peking University People’s Hospital (RDY 2021-21)
This publication has 44 references indexed in Scilit:
- Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burdenNature Communications, 2014
- Long non-coding RNAs: new players in cell differentiation and developmentNature Reviews Genetics, 2013
- Critical analysis of contemporary clinical research in muscle‐invasive and metastatic urothelial cancerCancer, 2013
- Genome Regulation by Long Noncoding RNAsAnnual Review of Biochemistry, 2012
- No-Nonsense Functions for Long Noncoding RNAsCell, 2011
- Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequencesJournal of Translational Medicine, 2010
- Bladder Cancer in 2010: How Far have We Come?CA: A Cancer Journal for Clinicians, 2010
- Evolution and Functions of Long Noncoding RNAsCell, 2009
- Disabled‐1 is a large common fragile site gene, inactivated in multiple cancersGenes, Chromosomes and Cancer, 2007
- Tyrosine phosphorylated Disabled 1 recruits Crk family adapter proteinsBiochemical and Biophysical Research Communications, 2004